Geode Capital Management
DMRA

Geode Capital Management’s Damora Therapeutics DMRA Stock Holding History

Geode Capital Management’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.1M Buy
965,364
+724,238
+300% +$17.5M ﹤0.01% 2015
2026
Q1 		$6.25M Buy
241,126
+229,553
+1,984% +$5.9M ﹤0.01% 2633
2025
Q4 		$266K Buy
+11,573
New +$201K ﹤0.01% 3817
2024
Q3 		– Sell
-8,565
Closed -$102K – 4554
2024
Q2 		$102K Buy
8,565
+232
+3% +$3.66K ﹤0.01% 4137
2024
Q1 		$163K Hold
8,333
– – ﹤0.01% 4004
2023
Q4 		$150K Hold
8,333
– – ﹤0.01% 4043
2023
Q3 		$150K Buy
8,333
+585
+8% +$23K ﹤0.01% 4095
2023
Q2 		$488K Buy
7,748
+3,390
+78% +$185K ﹤0.01% 3651
2023
Q1 		$217K Hold
4,358
– – ﹤0.01% 4007
2022
Q4 		$125K Buy
4,358
+113
+3% +$4.69K ﹤0.01% 4308
2022
Q3 		$200K Hold
4,245
– – ﹤0.01% 4213
2022
Q2 		$183K Buy
4,245
+358
+9% +$16.4K ﹤0.01% 4322
2022
Q1 		$213K Buy
3,887
+42
+1% +$2.36K ﹤0.01% 4348
2021
Q4 		$291K Buy
3,845
+912
+31% +$71.6K ﹤0.01% 4304
2021
Q3 		$263K Sell
2,933
-56
-2% -$5.99K ﹤0.01% 4326
2021
Q2 		$378K Buy
+2,989
New +$407K ﹤0.01% 4070

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Geode Capital Management's DMRA Position: Q2 2026 in Review

Geode Capital Management increased its Damora Therapeutics (DMRA) stake by 300% in Q2 2026, buying an estimated $17.5M and bringing the position to 965,364 shares worth $25.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2015.

Geode Capital Management first reported a position in DMRA in Q2 2021 and has held it in 16 quarters since. 104 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

  • Geode Capital Management held 965,364 shares of Damora Therapeutics worth $25.1M as of Q2 2026.
  • Geode Capital Management bought 724,238 Damora Therapeutics shares in Q2 2026, an estimated $17.5M.
  • Damora Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2015 holding.
  • Geode Capital Management first reported a position in Damora Therapeutics in Q2 2021 and has held it in 16 quarters since.
  • 104 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.